LYEL (STOCKS)
Lyell Immunopharma, Inc. Common Stock
$13.740000
-0.430000 (-3.03%)
Prev close: $14.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Lynn Seely
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $370.98M
- Employees
- 300
- P/E (TTM)
- -1.20
- P/B (TTM)
- 1.42
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-1.92 | $-2.06 | +0.1379 | +6.70% |
|
Mar 2026 (Q1)
|
$-1.10 | $-2.41 | +1.3123 | +54.40% |
|
Dec 2025 (Q4)
|
$-7.50 | $-2.28 | -5.2240 | -229.53% |
|
Sep 2025 (Q3)
|
$-2.13 | $-2.70 | +0.5654 | +20.98% |
Financial Statements
| Revenues | $27.00K |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $256.52M |
| Nonoperating Income/Loss | $8.02M |
| Operating Expenses | $256.52M |
| Operating Income/Loss | -$256.50M |
| Income/Loss From Continuing Operations After Tax | -$248.48M |
| Income/Loss From Continuing Operations Before Tax | $27.00K |
| Net Income/Loss | -$248.48M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$248.48M |
| Net Income/Loss Available To Common Stockholders, Basic | -$248.48M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$12.83 |
| Diluted Earnings Per Share | -$12.83 |
| Basic Average Shares | 64,649,000 |
| Diluted Average Shares | 64,649,000 |
| Assets | $311.15M |
| Current Assets | $213.54M |
| Noncurrent Assets | $97.61M |
| Fixed Assets | $30.51M |
| Other Non-current Assets | $67.11M |
| Liabilities | $77.34M |
| Current Liabilities | $39.87M |
| Accounts Payable | $3.88M |
| Other Current Liabilities | $35.99M |
| Noncurrent Liabilities | $37.47M |
| Equity | $233.82M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $233.82M |
| Liabilities And Equity | $311.15M |
| Net Cash Flow From Operating Activities | -$133.26M |
| Net Cash Flow From Operating Activities, Continuing | -$133.26M |
| Net Cash Flow From Investing Activities | $4.98M |
| Net Cash Flow From Investing Activities, Continuing | $4.98M |
| Net Cash Flow From Financing Activities | $102.47M |
| Net Cash Flow From Financing Activities, Continuing | $102.47M |
| Net Cash Flow | -$25.82M |
| Net Cash Flow, Continuing | -$25.82M |
| Comprehensive Income/Loss | -$248.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$248.69M |
| Other Comprehensive Income/Loss | -$69.12M |